Our unique process, paired withinnovation and continued improvement and evolution, puts us at the forefront.
Humacyte Awarded ‘Large Project Prototype of the Year’ from The Medical Technology Enterprise Consortium
Science Translational Medicine Publishes Results That Humacyte’s “Human Acellular Vessels Recellularize and Evolve into Living Blood Vessels following Human Implantation”
Humacyte Appoints Dr. Chris Fang as Chief Medical Officer
Humacyte to Present at the 37th Annual J.P. Morgan Healthcare Conference
From lower costs to fewer operations, HAVs may offer critical benefits.
With each year, we’ve movedcloser to lifesaving treatments.